Skip to main content
. 2017 Nov 6;53(1):29–37. doi: 10.1177/0018578717739397

Table 5.

Bleeding Events in the APEX Study Occurring ≤7 Days After Discontinuation of Study Drug.1

Bleeding event Betrixaban (n = 3716) Enoxaparin (n = 3716) Betrixaban versus
Enoxaparin relative risk
Major bleeding
 Any 0.67% 0.57% 1.19 (95% CI, 0.67-2.12)
(P = .554)
 Gastrointestinal bleeding 0.51% 0.24%
 Intracranial hemorrhage 0.05% 0.19%
 Intraocular bleeding 0% 0.03%
 Fatal bleeding 0.03% 0.03%
Clinically relevant nonmajor bleeding
 Any 2.45% 1.02% 2.39 (95% CI, 1.64-3.49)
(P < .001)